Abstract
Age-related macular degeneration (AMD) is a progressive retinal degenerative disease and a common cause of blindness. In AMD, there are two phenotypes; “atrophic (dry)” and “neovascular (wet)”. The former is characterized by the geographic atrophy due to death of retinal pigment epithelium, and the latter is developed due to choroidal neovascularization. While wet AMD can be treated by the inhibition of vascular endothelial growth factor or photodynamic therapy, so far there are no available treatments for dry AMD. Fortunately, understanding of pathogenesis in dry AMD has significantly been progressed and many candidates for the treatment of dry AMD have been introduced in clinical trials as well as preclinical stages. In this article, the progress of therapeutic approaches for dry AMD is reviewed.
Keywords: Age-related macular degeneration, complement, drusen, dry AMD, geographic atrophy, lipofuscin, retinal pigment epithelium
Current Molecular Pharmacology
Title: Dry Age-Related Macular Degeneration: Recent Progress of Therapeutic approaches
Volume: 4
Author(s): Noriyuki Kuno and Shinobu Fujii
Affiliation:
Keywords: Age-related macular degeneration, complement, drusen, dry AMD, geographic atrophy, lipofuscin, retinal pigment epithelium
Abstract: Age-related macular degeneration (AMD) is a progressive retinal degenerative disease and a common cause of blindness. In AMD, there are two phenotypes; “atrophic (dry)” and “neovascular (wet)”. The former is characterized by the geographic atrophy due to death of retinal pigment epithelium, and the latter is developed due to choroidal neovascularization. While wet AMD can be treated by the inhibition of vascular endothelial growth factor or photodynamic therapy, so far there are no available treatments for dry AMD. Fortunately, understanding of pathogenesis in dry AMD has significantly been progressed and many candidates for the treatment of dry AMD have been introduced in clinical trials as well as preclinical stages. In this article, the progress of therapeutic approaches for dry AMD is reviewed.
Export Options
About this article
Cite this article as:
Kuno Noriyuki and Fujii Shinobu, Dry Age-Related Macular Degeneration: Recent Progress of Therapeutic approaches, Current Molecular Pharmacology 2011; 4 (3) . https://dx.doi.org/10.2174/1874467211104030196
DOI https://dx.doi.org/10.2174/1874467211104030196 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chromatin Remodeling Agents for Cancer Therapy
Reviews on Recent Clinical Trials Co-formulation of P-glycoprotein Substrate and Inhibitor in Nanocarriers: An Emerging Strategy for Cancer Chemotherapy
Current Cancer Drug Targets Synergistic Interplay of Medicinal Chemistry and Formulation Strategies in Nanotechnology – From Drug Discovery to Nanocarrier Design and Development
Current Topics in Medicinal Chemistry Targeting SphK1 as a New Strategy against Cancer
Current Drug Targets Potentials of Hydrogels in Cancer Therapy
Current Cancer Therapy Reviews Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy Autophagy as a Molecular Target of Flavonoids Underlying their Protective Effects in Human Disease
Current Medicinal Chemistry Prolyl-Specific Peptidases and Their Inhibitors in Biological Processes
Current Chemical Biology MicroRNA Therapeutics: The Emerging Anticancer Strategies
Recent Patents on Anti-Cancer Drug Discovery Small Molecule Drugs and Targeted Therapy for Melanoma: Current Strategies and Future Directions
Current Medicinal Chemistry Search and Rescue: Identification of Cannabinoid Actions Relevant for Neuronal Survival and Protection
Current Neuropharmacology Neuropeptide-Derived Antimicrobial Peptides from Invertebrates for Biomedical Applications
Current Medicinal Chemistry Role of EGFR Monoclonal Antibodies in the Management of Non–small Cell Lung Cancer
Current Cancer Drug Targets Clinical Studies with Targeted Toxins in Malignant Glioma
Reviews on Recent Clinical Trials KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma
Current Neuropharmacology Matrix Metalloproteinase Inhibitor MMI-166 Suppresses the Growth of SW1990 Human Pancreatic Cancer Cells
Current Signal Transduction Therapy Radiolabeled Nanoparticles for Cancer Diagnosis and Therapy
Anti-Cancer Agents in Medicinal Chemistry Determination of Specificity and Biochemical Characteristics of Neutral Protease Isolated from Myceliophthora thermophila
Protein & Peptide Letters Plasticity of Neuroendocrine-Immune Interactions During Ontogeny: Role of Perinatal Programming in Pathogenesis of Inflammation and Stress- Related Diseases in Adults
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Mechanism of Anti-Tumor Effect by Curcumin in Hematological Malignancies
Current Pharmaceutical Analysis